Hemophilia B Pipeline Insight, 2020

Hemophilia B Pipeline Insight, 2020

DelveInsight has launched a new report on Hemophilia B Market Insights, Epidemiology and Market Forecast-2030

“Hemophilia B Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia B market. A detailed picture of the Hemophilia B pipeline landscape is provided, which includes the disease overview and Hemophilia B treatment guidelines. The assessment part of the report embraces in-depth Hemophilia B commercial assessment and clinical assessment of the Hemophilia B pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia B collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein.With the lack of this, the blood cannot clot properly to control bleedinglike hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

It is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. A male who has a hemophilia gene on his X chromosome will have hemophilia. When a female has a hemophilia gene on only one of her X chromosomes, she is a “hemophilia carrier” and can pass the gene to her children. Sometimes carriers have low levels of clotting factor and have symptoms of hemophilia, including bleeding. Clotting factors are proteins in the blood that work together with platelets to stop or control bleeding.

Request for :- free sample page

Pipeline Development Activities

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Hemophilia B with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Hemophilia B treatment.
  • Hemophilia B key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Hemophilia B market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 

Analytical Perspective 

  • In-depth Hemophilia B Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Hemophilia B Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.


Reports Key facts:- 

1.  According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.

2. Centers for Disease Control and Preventionstates Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.

3. As per Santoro, Cristina, et al.2018, the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5–3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.

Key companies working on Hemophilia B that are given below:-

1.  Novo Nordisk Pharma Co.

2.  CSL Behring Pharma Co. 

3.  Bioverativ Therapeutics (a Sanofi acquired company)

Drug names are given below:- 

1. Rebinyn

2. Idelvion

3. Alprolix

Table of contents

1. Report Introduction

2. Hemophilia B 

2.1. Overview

2.2. History 

2.3. Hemophilia B Symptoms

2.4. Causes


2.6. Hemophilia B Diagnosis 

2.6.1. Diagnostic Guidelines

3. Hemophilia B Current Treatment Patterns

3.1. Hemophilia B Treatment Guidelines

4. Hemophilia B – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hemophilia B Late Stage Products (Phase-III)

7. Hemophilia B Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hemophilia B Discontinued Products

13. Hemophilia B Product Profiles

14. Hemophilia B Key Companies

15. Hemophilia B Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Hemophilia B Unmet Needs

18. Hemophilia B Future Perspectives

19. Hemophilia B Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

22. About Delveinsight

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Hemophilia B.    
  • In the coming years, the Hemophilia B market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Hemophilia B R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Hemophilia B treatment market. Several potential therapies for Hemophilia B are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Hemophilia B market size in the coming years.  
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Hemophilia B) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Related Reports:-

1. Hemophilia B – Market Insight, Epidemiology and Market Forecast -2030

2. Hemophilia A – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/